Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

52.10 +0.42 (+0.81%)
Streaming Delayed Price Updated: 1:05 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Increased Prevalence of Atopic Dermatitis Fueling Impressive Growth for Atopic Dermatitis Drugs
Palm Beach, FL –November 30, 2021 – FinancialNewsMedia.com News Commentary – Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White... 
Via FinancialNewsMedia
Baidu Licenses Its Algorithm To Sanofi For mRNA Vaccine, Therapy Development
Baidu Inc (NASDAQ: BIDU) has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA (NASDAQ: SNY) for use in designing vaccine and... 
Via Benzinga
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
Pfizer Seeks Covid Boosters For All; But How Long Is The Opportunity?
Both vaccine stocks popped after Pfizer asked for booster authorization in all adults. 
Via Investor's Business Daily
Sanofi (SNY) Q3 2021 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Sanofi Raises FY21 Earnings Outlook As Dupixent, Vaccines Boost Q3 Performance
Sanofi SA's (NASDAQ: SNY) Q3 sales grew 10.1% Y/Y to €10.4 billion due to solid growth from Dupixent, Vaccines, and Consumer Healthcare. EPS for the... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine... 
Via Benzinga
Exposures Product Safety
Bitcoin Futures Arrive
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
Exposures Product Safety
Regeneron Could Have a Big Catalyst Coming in 2022
Cancer drug Libtayo could receive FDA approval for its fourth indication in January. 
Via The Motley Fool
Exposures Product Safety
Will Chart Analysts Notice Bad Omen on Sanofi's Chart
If history is any guide, there may be trouble ahead for shares of Sanofi(NASDAQ:SNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
Denali Therapeutics Inc (NASDAQ: DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was generally... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 6, 2021 – USA News Group – As vaccine passport programs continue to roll out in new markets across the globe, especially in... 
Via FinancialNewsMedia
Exposures COVID-19
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Multiple Bits Of Bad News
Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser. 
Via Talk Markets
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi... 
Via Benzinga
Exposures COVID-19
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Mond... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ: 
Via Benzinga
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
Pfizer Nabs Booster OK In U.S. — But How Long Will It Hold The Covid Lead?
The FDA allowed the Pfizer-BioNTech Covid booster for some. But rivals are coming. 
Via Investor's Business Daily
Exposures Product Safety
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. ... 
Via Benzinga
AbbVie's Pain Is Sanofi's and Regeneron's Gain
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors. 
Via The Motley Fool
Exposures Product Safety
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.